ClinicalTrials.gg
CompletedNCT04156048HIV&HEARTUpdated Feb 5, 2020

HIV&HEART Aging Study (12,5 Year Follow up)

An observational study in HIV Infections, Coronary Disease and Myocardial Infarction, sponsored by University Hospital, Essen. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Primary conditionAIDS Dementia ComplexRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
AIDS Dementia Complex
Why
  1. The study's listed conditions name AIDS Dementia Complex, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Essen · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,809
Ages
18 Years and older
Sex
All
01

Study summary

The HIV/HEART Aging study (HIVH) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (CVD) in HIV-infected patients. The study population includes outpatients from specialized HIV-care units of the German Ruhr region, who were at least 18 years of age, were known to have a HIV-infection and exhibited a stable disease status within 4 weeks before inclusion into the trial. From March 2004 (Pilot phase) to October 2019 (12,5 year Follow-up) 1806 HIV+ patients were recruited in a consecutive manner. The standardised examinations included a targeted assessment of medical history and physical examination. Blood was drawn for comprehensive laboratory tests including HIV specific parameters (CD4 cell count, HIV-1 RNA levels) and cardiovascular items (lipid concentrations, BNP values and renal parameters). Furthermore, non-invasive tests were performed during the initial visit, including additional heart rate and blood pressure measurements, electrocardiogram (ECGs) and transthoracic echocardiography (TTE). Examinations were completed in accordance with previously defined standard operating procedures. CVD were defined as coronary, cerebrovascular, peripheral arterial disease, heart failure or cardiac vitium.

Read the detailed description

A comprehensive detailed description of the study procedures had been previously published (European Journal of medical research 2007;12:243-248).

Comprehensive non invasive cardiovascular examination

  • Anamnesis
  • File recherche,Physical examination
  • Documentation of the cardiovascular and antiretroviral medical therapy
  • Electrocardiogram
  • Transthoracic echocardiography
  • Exercise electrocardiogram
  • Exercise Montreal Cognitive Assessment test
  • Exercise the Grooved Pegboard test
  • Blood collection
  • Questionnaire to quality of life and health economics
02

Conditions studied

  • HIV Infections
  • Coronary Disease
  • Myocardial Infarction
  • HIV Encephalopathy
  • Aging
  • Heart Failure

Keywords

  • HIV
  • AIDS
  • Antiretroviral therapy
  • Aging
  • Heart failure
  • coronary heart disease
  • myocardial infarction
  • HIV-associated neurocognitive disorders
03

In context

AIDS Dementia Complex Reclassified

41 studies on the registry are indexed under AIDS Dementia Complex; 2 are open to participants now.

Browse AIDS Dementia Complex studies →

Lead sponsor

University Hospital, Essen is the lead sponsor of 118 studies on the registry; 35 are open to participants now.

Compared within AIDS Dementia Complex, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

population affected by HIV

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Known -infection
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Acute cardiovascular disease
  • Unstable hemodynamic status in the three weeks before inclusion
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,809 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Cardiovascular Diseases in HIV-infected Patients

    Time frame: Baseline up to 12,5 year follow up

Secondary outcomes

  1. Impact of classic cardiovascular risk factors of coronary artery disease, comorbidities and antiretroviral therapy

    Time frame: Baseline up to 12,5 year follow up

  2. Impact of new HIV-specific risk factors of coronary artery disease, comorbidities and antiretroviral therapy

    Time frame: Baseline up to 12,5 year follow up

07

Study locations

6 sites
  • Institut für Medizinische Informatik, Biometrie und Epidemiologie
    Essen, Nordrhein-Westfalen 45147, Germany
  • Universitätsklinikum Essen, Klinik für Dermatologie
    Essen, Nordrheinwestfalen 45147, Germany
  • University Hospital of Bochum, Department of Dermatology
    Bochum, NRW 44791, Germany
  • HIV physician pratice
    Duisburg, NRW 47259, Germany
  • Clinical Coordinating Center Leipzig
    Leipzig, Sachsen 04107, Germany
  • HIV Outpatient Department
    Dortmund, 44137, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Oct 2019, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Nov 7, 2019
StartActual
Jul 3, 2017
Primary completionActual
Oct 31, 2019
CompletionActual
Nov 6, 2019
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04156048
Responsible party
Stefan Esser M.D. (PD Dr. med. Stefan Esser, University Hospital, Essen) — Principal investigator
First posted
Nov 7, 2019
Start date
Jul 3, 2017
Primary completion
Oct 31, 2019
Completion
Nov 6, 2019
Last update
Feb 5, 2020

Study contacts

Stefan Esser, PD, MD
principal investigator · Departement of dermatology and venerology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion